fenofibrate (Tricor, etc) for slowing progression of diabetic retinopathy

There's interest in using fenofibrate (Tricor, etc) for slowing progression of diabetic retinopathy.

Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults.

A new subgroup analysis of the FIELD trial shows that type 2 diabetes patients taking fenofibrate are a third less likely to need laser treatment for retinopathy. This translates into to a 1.5% absolute risk decrease...or that 67 patients would need to be treated with fenofibrate instead of placebo to prevent one laser treatment.